Patients with lupus nephritis (LN), (28 studies).
Systematic review to evaluate the efficacy and safety of intravenous immunoglobulin (IVIg).
Various comparisons, including: indications for use, and dosage.
When the studies were evaluated, IVIg therapy was found to be between 60% to 70% effective (except for patients with class V LN) with overall responses (complete + partial) even for patients who were refractory to first line treatment. Normalization (<0.5 g) of nephrotic proteinuria occurred in 24% of cases with infrequent adverse events and a mortality plus dialysis composite of 11.5% and 24.1% (most representative study).